As a member of the selectin family, CD162/PSGL-1 is mainly expressed in some immune or inflammatory cells. CD162/PSGL-1 deficiency affects myeloid differentiation and lymphocyte maturation and therefore has important implications for cell differentiation. CD162/PSGL-1 can be used as an immune checkpoint modulator and may be a new target for cancer therapy. CD162/PSGL-1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD162/PSGL-1 protein, expressed by HEK293 , with C-His labeled tag.
